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Strengths and limitations of this study
 ► To our knowledge this is the first qualitative evi-
dence synthesis of patients’ experiences of taking 
opioid medications.
 ► Meta- ethnography provides a thorough, systematic 
way of synthesising qualitative findings across mul-
tiple studies.
 ► Meta- ethnography provides the reviewer’s interpre-
tation of second- order concepts.
 ► Using a GRADE- CERQual (Grading of 
Recommendations Assessment, Development and 
Evaluation working group - Confidence in Evidence 
from Reviews of Qualitative research) approach can 
assist in rating confidence in the review findings.
 ► Qualitative research that illuminates patients’ per-
spectives can help to shape future approaches to 
opioid management.
AbStrACt
Objective To review qualitative studies on the experience 
of taking opioid medication for chronic non- malignant pain 
(CNMP) or coming off them.
Design This is a qualitative evidence synthesis using 
a seven- step approach from the methods of meta- 
ethnography.
Data sources and eligibility criteria We searched 
selected databases—Medline, Embase, AMED, Cumulative 
Index to Nursing and Allied Health Literature, PsycINFO, 
Web of Science and Scopus (Science Citation Index and 
Social Science Citation Index)—for qualitative studies 
which provide patients’ views of taking opioid medication 
for CNMP or of coming off them (June 2017, updated 
September 2018).
Data extraction and synthesis Papers were 
quality appraised using the Critical Appraisal Skills 
Programme tool, and the GRADE- CERQual (Grading 
of Recommendations Assessment, Development and 
Evaluation working group - Confidence in Evidence from 
Reviews of Qualitative research) guidelines were applied. 
We identified concepts and iteratively abstracted these 
concepts into a line of argument.
results We screened 2994 unique citations and 
checked 153 full texts, and 31 met our review criteria. 
We identified five themes: (1) reluctant users with little 
choice; (2) understanding opioids: the good and the bad; 
(3) a therapeutic alliance: not always on the same page; (4) 
stigma: feeling scared and secretive but needing support; 
and (5) the challenge of tapering or withdrawal. A new 
overarching theme of ‘constantly balancing’ emerged from 
the data.
Conclusions People taking opioids were constantly 
balancing tensions, not always wanting to take opioids, 
and weighing the pros and cons of opioids but feeling they 
had no choice because of the pain. They frequently felt 
stigmatised, were not always ‘on the same page’ as their 
healthcare professional and felt changes in opioid use 
were often challenging.
trial registration number 49470934; Pre- results.
IntrODuCtIOn
Chronic non- malignant pain (CNMP) 
affects between an estimated 11% and 20% 
of the population in Europe and USA and 
can impact heavily on people’s quality of 
life.1 2 Opioid medications are strong pain-
killers which have a well- established role 
in the treatment of acute and cancer pain; 
they have also been advocated for CNMP. 
Opioids can have distressing side effects as 
dosages increase, such as constipation, seda-
tion, drowsiness, nausea, decreased concen-
tration and memory, or mood changes.3 
Most people who use opioids develop toler-
ance to the painkilling effect of opioids, and 
some become dependent on them. Studies 
have shown that high opioid usage can also 
put people’s lives at risk.4 Despite this, the 
prescription of opioid medication for CNMP 
has risen sharply in the higher income coun-
tries. Few studies of opioids have shown 
effectiveness beyond 12 weeks of follow- up. 
Population surveys have shown long- term use 
to be associated with increased side effects 
and limited pain relief.3 5 6
This synthesis of qualitative research was 
undertaken to underpin a process evaluation 
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box 1 Inclusion and exclusion criteria
Included studies.
 ► Adults (18 years or older) taking or have taken opioid medication in 
the last 5 years.
 ► Published in English in peer- reviewed journals with no time 
constraints.
 ► Must relate to patient perspectives on using opioid medication for 
chronic non- malignant pain.
 ► Must use qualitative methodology (any analytical approach) or 
mixed quantitative and qualitative methodology with qualitative 
findings reported separately.
 ► Where studies include participants with differing medication, we 
will include studies where the experience of those taking opioids is 
reported separately.
Excluded studies.
 ► Paediatric studies (age less than 18 years).
 ► Theoretical or methodological papers.
 ► Purely quantitative studies or mixed methods studies where the 
qualitative data are not presented separately.
 ► Studies concerning active cancer.
 ► Studies concerning headache.
 ► Studies concerning any acute, or acute postoperative, pain.
 ► Studies concerned only with healthcare professional or carer per-
spectives, or studies of mixed carer/patient/professional popula-
tions where patient perspectives are not presented separately.
 ► Non- English- language studies.
 ► Theses or conference abstracts which are not peer- reviewed.
for the I- WOTCH (Improving the Wellbeing of people 
with Opioid Treated CHronic pain) study. I- WOTCH is 
a randomised controlled trial evaluating a multicompo-
nent education and patient- centred group intervention 
with a one- to- one tapering programme against a control 
of an advice booklet with a relaxation CD. More informa-
tion can be found in the main study protocol7 and process 
evaluation protocol.8 This qualitative evidence synthesis 
uses the methods of meta- ethnography to find out what 
people’s experiences are of both using opioids for CNMP 
and their attempts to stop taking them.
MEthODS
We use Noblit and Hare’s9 seven stages of meta- 
ethnographic analysis. We used the new Meta- Ethnog-
raphy Reporting Guidelines (eMERGe) to structure our 
report10 (see online supplementary appendix 1). The 
protocol is published in the International Prospective 
Register of Systematic Reviews (PROSPERO) (http://
www. crd. york. ac. uk/ PROSPERO). CRD42017082418
Step 1: getting started
In order to address what has been labelled an opioid 
epidemic,11 we need to understand people’s experiences 
of being on opioids and of coming off them. Our team 
was chosen because of its expertise in primary qualitative 
research and qualitative evidence synthesis specific to 
chronic pain and opioid prescription.
Step 2: deciding what is relevant
We undertook systematic electronic searches in June 
2017, with a rerun in September 2018, appraising rele-
vant papers for quality using the Critical Appraisal Skills 
Programme (CASP) tool for qualitative research.12 One 
researcher (VPN) with the assistance of an academic 
librarian (SJ) searched seven electronic databases: 
Medline, Embase, Allied and Complementary Medicine 
Database (AMED), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), PsycINFO, Web of 
Science and Scopus (Science Citation Index and Social 
Science Citation Index). Forward citation searches were 
also conducted. We used search terms, free text and 
medical subject headings (MeSH) terms for all opioid 
drugs as well as their generic names. We combined these 
with the MeSH term ‘pain’ and a wide range of MeSH 
terms and words to describe all types of qualitative 
research and its analysis based on a search used by Toye 
et al in 2017.13 The search was limited to those in English 
and on humans, with no cut- off date. Online supplemen-
tary appendix 2 shows an example of our search terms.
Unique citations were screened independently by two 
researchers (VPN and ST; see the Acknowledgements 
section) against our inclusion and exclusion criteria (see 
box 1). Any disagreements were arbitrated by a third 
researcher (KS). Papers for full- text reading were iden-
tified and read by two researchers. Quality was assessed 
using the CASP tool. VPN critically appraised the studies 
and KS independently appraised 10% for consistency. 
The CASP scores are shown in table 1 and online supple-
mentary appendix 3. The GRADE- CERQual (Grading of 
Recommendations Assessment, Development and Eval-
uation working group - Confidence in Evidence from 
Reviews of Qualitative research) was used to appraise the 
reviewers’ confidence in the research findings.14 15
Step 3: reading the studies
VPN read all the studies, and KS and FT read half of these 
papers each (so all were read twice), and all extracted 
the second- order concepts independently. A second- 
order concept is a researcher’s interpretation of data in a 
primary qualitative study.16 VPN, KS and FT met to discuss 
and reach agreement, and compiled a spreadsheet of all 
of the concepts extracted from the papers.
Step 4: determining how the studies are related
VPN sorted the concepts into categories by looking for 
any similarities and differences across all the studies. 
VPN, KS and FT discussed the categorisation of data on 
multiple occasions. To enable comparison across studies, 
VPN recorded descriptive data about each study (see 
table 1).
Step 5: translating studies into each other
Patterns and associations between categories were 
explored, and all researchers felt that a line of argument 
approach as defined by Noblit and Hare9 would be the 
most useful method to interpret the data.
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Figure 1 Concept model of the experiences of people taking opioid medication for chronic non- malignant pain.
Step 6: synthesising translations
Agreement was reached by clearly defining the overar-
ching or third- order concepts arising from the data. A 
third- order concept is the reviewer’s interpretation of 
second- order concepts.
Step 7: expressing the synthesis
We developed a conceptual model to show how the 
themes related to each other in a line of argument (see 
figure 1).
Patient and public involvement
We did not involve patients or the public in our work.
rESultS
Two reviewers (VPN and ST) screened 2994 titles or 
abstracts (after the removal of duplicates from the 5064 
citations retrieved) and identified 153 full texts of interest. 
Two reviewers (VPN and KS) read these and 122 were 
excluded. Reasons are given in the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses flow 
chart (see figure 2). The reviewers agreed to include 31 
studies. The included studies were from the USA (23), 
Canada (4) UK (2) and Australia (2), and used a range of 
qualitative methods.
We report the four facets of GRADE- CERQual for all 
papers: (1) methodological, (2) confidence, (3) rele-
vance and (4) adequacy of data (see tables 2 and 3).
Synthesis of findings
We abstracted five themes from the second- order 
concepts. Table 4 shows how each study contributed to 
each theme. We have illustrated each concept with exem-
plary quotations.
reluctant users with little choice
This describes a resistance or hesitancy to take opioids 
mainly due to concerns about side effects or addiction, 
although they felt there were no other options available.
I don’t want to become addicted, if I’m going to be-
come addicted then as far as I’m concerned I’m a 
druggie, so I might as well not be here anyway, so I 
don’t want to become addicted…. (Blake et al, p103)17
I just didn’t want to go on them because I mean once 
you get on them that’s it, you’re sort of stuck on them. 
I didn’t want to take morphine at first because there 
was a girl that I went through one of the courses with 
and she always seemed really dopey and drugged up 
so it took them a long while to talk me to into taking 
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Figure 2 PRISMA flow diagram.52 PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses.
the morphine because I didn’t want to be like that. 
(Zheng et al, p1832)18
Some spoke of underusing or were keen to reduce their 
medications when possible. There was a dislike of being 
on long- term medication and some thought that it would 
not relieve their pain.
I don’t want to do that [take more morphine]. I want 
to stay on as little as I possibly can because there 
might come a time when I need more and I don’t 
want to be on high doses. I’ve always tried to keep it 
at a minimum amount of tablets each day…. (Blake 
et al, p105)17
Even though some were reluctant, there were other 
instances of dramatic improvement in people’s lives. This 
then weighted their choice to stay on the opioids.
I mean it is just like a miracle as far as I am con-
cerned. It is like knowing it [the pain] is there but 
you have the instruments to prevent it from getting 
out and [be]coming a roaring demon. (Vallerand 
and Nowak, p170)19
But opiates, that’s my way of life. There would be no 
life if I didn’t have this. And I thank God for them 
because without them I’d be…well I wouldn’t be. I 
just couldn’t go on. I would have committed suicide 
a long time ago. And I say that truthfully cause you 
could not live like that, with that constant, constant 
pain. But, with the opiates it’s made it possible to be 
able to have a part of a life, you know. (Brooks et al, 
p20)20
understanding opioids: the good and the bad
This describes patients’ knowledge or understanding 
about opioids which had generally been acquired ad hoc 
and slowly over time, from pharmacists, patient package 
inserts in their medication, leaflets, the internet, televi-
sion programmes and from doctors, especially doctors at 
the pain clinic.
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Table 2 Confidence in review findings: GRADE- CERQual assessment
Review findings
Studies contributing
(see table 1 column 1 for 
study number)
Methodological 
limitations (study 
number)
Relevance (see 
table 1 end 
column) Coherence
Adequacy of 
data
Reluctant users with little 
choice
1, 3, 4, 5, 6, 7, 17, 18, 21, 
22, 26, 27, 30 (13 studies)
11 no concerns.
2 minor concerns (18, 
22).
5 Relevant.
6 Partial.
2 Indirect.
No concerns. No concerns.
Understanding opioids: the 
good and the bad
1, 3, 7, 9, 10, 11, 15, 16, 17, 
23, 25, 27, 29 (13 studies)
12 no concerns.
1 minor concerns (23).
6 Relevant.
6 Partial.
1 Indirect.
No concerns. No concerns.
A therapeutic alliance: not 
always on the same page
1, 2, 3, 4, 5, 7, 9, 10, 11, 13, 
14, 15, 16, 17, 18, 19, 20, 
21, 22, 23, 24, 25, 26, 28, 
29, 31 (26 studies)
23 no concerns.
3 minor concerns (18, 
22, 23).
12 Relevant.
11 Partial.
3 Indirect.
No concerns. No concerns.
Stigma: feeling scared 
and secretive but needing 
support
1, 2, 3, 4, 7, 9, 10, 14, 16, 
17, 18, 20, 21, 22, 23, 24, 
27, 28, 31 (19 studies)
16 no concerns.
3 minor concerns (18, 
22, 23).
  10 Relevant.
  8 Partial.
  1 Indirect.
No concerns. No concerns.
The challenge of tapering/
withdrawal from opioids
7, 10, 18, 19, 30, 31 (6 
studies)
5 no concerns.
1 minor concerns (18).
2 Relevant.
4 Partial.
Minor 
concerns.
Minor 
concerns.
GRADE- CERQual, Grading of Recommendations Assessment, Development and Evaluation working group - Confidence in Evidence 
from Reviews of Qualitative research.
Table 3 GRADE- CERQual component scoring
Methodological limitations.
Coherence.
Adequacy of data.
No or very minor concerns.
Minor concerns.
Moderate concerns.
Serious concerns.
Relevance. Relevant.
Partial.
Indirect.
Uncertain.
GRADE- CERQual, Grading of Recommendations Assessment, 
Development and Evaluation working group - Confidence in 
Evidence from Reviews of Qualitative research.
When you see it in the media, when you see it on the 
television, you think if you’re taking regular mor-
phine you must be in a pretty bad way, you know. 
(Blake et al, p103)17
I always ask before I go on a medication, what are 
the side effects, I was told I may experience constipa-
tion; nothing else was explained to me. (Paterson et 
al, p721)21
There was often poor knowledge about using opioids 
for chronic pain, and about addiction, overdose risk and 
side effects.
There’s not too much education about it [over-
dose]…When I first started taking it [the opioid 
medication], no one told me about OD [overdose] or 
anything about that. Because I was taking it not [as] 
prescribed…I was just like when I felt pain I would 
just take like five or six of them or whatever. Then at 
the end, I’d run out. (Mueller et al, p279)22
Patients often had to defend their usage and this added 
to their stress especially when they felt their healthcare 
professionals lacked an understanding of the place for 
opioids in the treatment of CNMP or were cautious about 
using them.
The concern is that if they increase my opioid dosage, 
I could stop breathing. It’s ridiculous. (Frank et al, 
p1841)23
There are still a lot of doctors out there that are 
against it. They think it is bad. Bad medicine. Bad 
practice. (Vallerand and Nowak, p129)24
In contrast, some people felt well informed, which 
either produced more concern or gave the patients confi-
dence in their opioid regimen.
… and from what I’ve read up, because I like to, sort 
of, keep on top of things, that it’s an opium based 
drug, so you will build up some tolerance and you will 
build up [becomes tearful] And you will potentially 
become sort of addicted to it, if you like. (McCrorie 
et al, p3)25
Under Dr A [pain clinic] I’ve learnt more. And my 
concern has been, well it was initially the possibility 
of addiction, but she has assured me that I’m not 
showing no signs of addiction at all. I may have some 
withdrawal problems. (Paterson et al, p721)21
A therapeutic alliance: not always on the same page
This describes a therapeutic alliance or the relationship 
between patients and their healthcare providers, which 
was considered important.
Overall there was a feeling that healthcare profes-
sionals and patients were often ‘not on the same page’ 
about opioid usage.
My family doctor…does not want me to be depen-
dent on heavy pain meds, so I am intensely miserable 
99% of the time. (Warms et al, p252)26
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Table 4 Themes apparent in each study
Author RU U TA S TW
1. Arnaert and Ciccotosto30 X X X X
2. Bergman et al29     X X
3. Blake et al17 X X X X
4. Brooks et al20 X   X X
5. Buchbinder et al39 X   X   
6. Chang et al40 X       
7. Chang and Ibrahim31 X X X X X
8. Coyne et al41         
9. Esquibel and Borkan42   X X X
10. Frank et al23   X X X X
11. Green et al43   X X   
12. Hooten et al44         
13. Krebs et al27     X   
14. Matthias et al45     X X
15. McCrorie et al25   X X   
16. Mueller et al22   X X X
17. Paterson et al21 X X X X
18. Penney et al28 X   X X X
19. Rieb et al34     X   X
20. Simmonds et al46     X X
21. St Marie47 X   X X
22. Vallerand and Nowak19 X   X X
23. Vallerand and Nowak24   X X X
24. Wallace et al48     X X
25. Warms et al26   X X   
26. Zgierska et al49 X   X   
27. Zheng et al18 X X   X
Studies from search rerun RU U TA S TW
28. Al Achkar et al32     X X X
29. Matthias et al33   X X   X
30. Matthias et al50 X         
31. Smith et al51     X X   
RU, reluctant users with little choice; S, stigma: feeling scared and secretive but needing support; TA, a therapeutic alliance: not always on the same page; 
TW, the challenges of tapering or withdrawal; U, understanding opioids: the good and the bad; X, theme present in the paper.
Some patients felt they were not listened to and were 
frustrated by a lack of empathy from physicians regarding 
their pain experience.
I frequently have difficulty with the residents (doc-
tors in training) explaining why these drugs, this 
many drugs…Finally Dr. [family physician] wrote 
a note in my file – stop harassing [participant’s 
name]. This is what she gets and why she gets it. And 
they did stop but it was inconvenient. For instance, 
they would not prescribe me three months at a time. 
I would be dispensed one month at a time. And for 
someone who had been taking the same drugs for 
10 years I found that condescending. (Brooks et al, 
p18)20
A reluctance to prescribe from general practitioners 
and pharmacists and the use of opioid contracts or a 
restriction of medication were often considered punitive.
It kind of made me feel like I was doing something 
wrong, which I wasn’t, but I signed a contract. You 
know, what would I be without my meds? (Krebs et al, 
p1152)27
And I told my doctor that, that I wanted so I could 
sleep through the night. And now he, well, I’ll give 
you 10, but it’s got to last. Like he treats me like a 
drug addict. (Penney et al, p6)28
The healthcare system often worked against a thera-
peutic alliance with lack of continuity or care or frequent 
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visits, which fed into mistrust. Patients complained that 
provider turnover affected their ability to receive indi-
vidualised care; conversations about pain and treatment 
options often had to be started over again from scratch.
I don’t have the same doctor long enough to know. 
(Bergman et al, p1693)29
However having blood or urine tests for levels of opioids 
and regular checks were seen by some as being cared for.
I would say, ‘I have this agreement and you don’t have 
to sign it if you don’t want to, but I would like to go 
over it with you. These are suggestions because this 
medication is addictive, it is dangerous, and I just 
want to make sure you’re aware.’ I think if you really 
want to make it where people are not hostile, say they 
have to have a urine test every 6 months, everybody, 
and that ‘it’s a policy because we care about all of 
you.’ (Krebs et al, p1152)27
Some talked of the need for good relationships built on 
trust, shared decision making and knowledgeable special-
ists who communicate well.
I wouldn’t say I researched it to that depth, you know, 
I read a little bit about, and asked a lot of questions 
at my doctor, and then we decided. (Paterson et al, 
p722)21
Stigma: feeling scared and secretive but needing support
This describes feelings of stigma and fear which people 
expressed directly in relation to their opioid usage. This 
includes people’s negative attitudes from family, medical 
professionals and work colleagues which lead to them 
feeling stigmatised and judged for taking opioids.
So I’m constantly trying to clean up because I think 
people are going to judge me. ‘Oh, because she’s on 
all this medication, ooh, she can’t look after her chil-
dren.’ (Paterson et al, p724)21
As soon as you mention to someone that you are on 
pain medication it’s, ‘Oh my god, you’ve got to get off 
it.’ It is viewed as weak. Somehow I am weak for being 
on this medication. (Vallerand and Nowak, p128)24
To protect themselves, some chose to keep their opioids 
a secret.
But you know, after 2 years of pain, you are physically 
exhausted, mentally exhausted and depressed. So, I 
take my medication and I hide it at the bottom of 
my drawer. It’s my secret life. It’s always a secret, and 
I’ve got to hide it and not tell anyone. (Vallerand and 
Nowak, p169)19
Some people made a conscious decision about who 
they could tell and who they could not due to nega-
tive reactions. Relationships suffered when patients felt 
unsupported.
My son told me I was a drug addict. He did. He real-
ly did. He was to the point, he didn’t know what he 
could do for me. It really was that bad. (Vallerand and 
Nowak, p128)24
I had originally told my sister and she was very con-
cerned. Then she said, ‘As long as you don’t stay on 
them.’ She thought it was OK if I did it for a while 
but as long as I didn’t stay on them. So I just sort of 
never told her. And she never asked. (Vallerand and 
Nowak, p128)24
Although some seemed confident in using opioids, 
mostly people spoke about fears such as addiction and 
uncontrolled pain. Feeling supported validated their 
choices and experiences and lessened some of their fears 
and concerns.
And at the end, my partner says—we sat down there 
and he goes ‘Stay on them.’ …I’ve always spoke to my 
partner, and if he’s been unsure—we’ve both been 
unsure, we’ve both gone into the doctor together to 
ask questions. (Zheng et al, p1834)18
my wife wanted me to take this medication. She was 
like: let’s go for it. (Arnaert and Ciccotosto, p26)30
the challenge of tapering/withdrawal from opioids
Four papers23 31–33 explored patients’ experiences of 
tapering or withdrawing as their main content. Two 
further papers28 34 addressed it as a more peripheral issue 
(see CERQual ratings in table 2). This describes the chal-
lenges and profound effects of tapering or withdrawing 
from opioids.
Tapering and withdrawing from opioids could be chal-
lenging and provoke anxiety.
I have a tremendous fear in a doctor saying I want 
you to taper off the methadone and get totally off the 
methadone with no alternative whatsoever. I think 
that would be an irrational decision by a doctor, and 
I probably wouldn’t take that advice. (Frank et al, 
p1842)23
This anxiety could be alleviated by support from a 
trusted healthcare provider or other person.
The best thing about it was that nobody acted like 
I was a bad person because I was on these medica-
tions and was having to be going through this really 
slow process of coming down off of them. (Frank et 
al, p1843)23
Successful tapering was described as a collaborative 
agreement between the healthcare professional and the 
patient.
She put me down to 2 and a half [pills per day]. Then 
she said, okay, we’ll go down to half a pill. I told her I 
didn’t think that just 2 a day would do it, and she said 
okay, we’ll try 2 and a half, are you agreeable with 
that? I said that’s fine. I mean, we can discuss stuff. 
It doesn’t have to be a disagreement because we can 
 o
n
 February 24, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032988 on 18 February 2020. Downloaded from 
12 Nichols VP, et al. BMJ Open 2020;10:e032988. doi:10.1136/bmjopen-2019-032988
Open access 
talk about it. It’s not an argument. We’re 2 adults hav-
ing a conversation, figuring out what to do. (Matthias 
et al, p1368)33
However, not all people experienced joint decision 
making when tapering.
I just don’t feel that he’s understanding. he don’t 
seem to care what I’m saying, because he’s lowering 
it down anyway, even though I’ve told him…that I 
didn’t agree with it being lowered. (Matthias et al, 
p1369)33
For those in the USA, prescribing policies, advising 
clinicians to monitor and decrease opioid use, and the 
legislation to enforce these policies made those taking 
opioids feel as if they were ‘a public health problem’. 
This could have a negative effect on the doctor–patient 
relationship and leave the patient feeling disempowered. 
This was compounded when opioids had been withdrawn 
by legislation.31 32
I have to struggle, suffer, to make the next the next 
time that I can get my medicine. And I don’t think 
that’s fair to me because if I can take my medicine a 
little more regularly, I would be able to do more…I 
don’t think that the law, people, politicians, or any-
body should be able to tell anybody that’s in pain 
what type of medicine they can take. (Al Achkar et 
al, p7)32
That kinda got me mad, cause I thought well you 
know…they’re taking it off the market because of 
people abusing it…It’s not fair to us, you know…I 
think the government was wrong to…pull them off 
the market, you know, because of people abusing 
them, no like they weren’t looking at the people that 
need them…But I think it’s really unfair that people 
that really do need them can’t get them. (Chang and 
Ibrahim, 2017, p3)31
Overarching theme: constantly balancing
After considering the fives themes, an overarching theme 
emerged: ‘Constant balancing’. The theme reluctant users 
with little choice describes the need to balance the pros and 
cons of starting opioids and the need to balance having 
pain with their hesitancy to use opioids.
I don’t really like being on a lot of tablets, I’ve never 
been a tablet person, um…but I mean I can’t have 
the pain either so it’s one evil outdoing the other evil. 
(Paterson et al, p723)21
Studies describe balancing the dose for pain manage-
ment with their side effects to allow them to function. 
Participants constantly weighed up the effects on their 
life: dealing with an internal conflict of unresolved pain 
versus necessary medication, being opioid free versus 
having uncontrolled pain, and balancing other stressors 
against opioid dose changes.
If you’re going to be able to walk, and you take one 
pain pill so you can walk and live life, you’re going to 
do it, even though you may not like it. (Penney et al, 
p6)28
The theme stigma: feeling scared and secretive but needing 
support describes the need to balance their hopes for 
relief with fear of side effects, and also to balance whether 
or not to disclose their opioid use with the risk of being 
labelled a ‘drug seeker’ versus having unrelieved pain.
I do it for my own protection by not telling them be-
cause I see how they react by reading something in 
the paper…and it’s just their ignorance. And I don’t 
have time. Well they know what’s going on but they 
don’t get it to this day. So you have to pick your bat-
tles…. (Brooks et al, p19)20
The theme understanding opioids: the good and the bad 
showed people had different levels of understanding, but 
weighed up their decisions and trade- offs against their 
pain relief.
It’s, it’s got a good and bad side, morphine.…When 
I take it, it works really, really well but it makes you 
feel rather sick, umm, rather spaced out and thinking 
wise, umm, it outcomes more on the other, do I want 
to be sick or do I want to cry with pain? So I’d rather 
be sick but it is a very, very good painkiller. (Blake et 
al, p105)17
The therapeutic alliance theme showed that often it 
was evident that they were ‘not on the same page’, with 
them balancing the advice from their doctors with what 
they wanted.
[My provider] said you could die any time, and my 
husband and I said, well, we realize that, but because 
of the pain, you know, we were willing to take that 
risk that I would die from the narcotic medication. 
(Frank et al, p1841)23
It also meant that there were multiple barriers to 
the process of decreasing opioids due to this constant 
balancing act, which is described in the theme the chal-
lenge of tapering/withdrawal from opioids.
I will tell her, if I do come off this medication, there 
are going to be consequences. I can’t walk as often, I 
can’t stand as long, I just can’t do it…. (Vallerand and 
Nowak, p169)19
DISCuSSIOn
Our five themes were (1) reluctant users with little 
choice; (2) understanding opioids: the good and the 
bad; (3) a therapeutic alliance: not always on the same 
page; (4) stigma: feeling scared and secretive but needing 
support; and (5) the challenge of tapering or withdrawal. 
An overarching theme of ‘constantly balancing’ emerged 
from the data. These themes all had positive and negative 
aspects, although the negative were more prevalent .
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We present a line of argument of how complex it is for 
the patient to balance decisions at every stage of their 
journey. First is their reluctance to start taking opioids 
but feeling they had no option. Patients are given opioids 
for CNMP often as a last resort when all other treatment 
has failed and their lives are so profoundly affected that 
they talk of a desperation, that they would literally ‘try 
anything’. Patients spoke about not being given any 
detailed information about opioids and that they had 
learnt more about them over time from different sources. 
This varied understanding about opioids and their side 
effects can affect the decisions that people make. Patients 
reported the need to keep the dosage of opioids as low as 
possible and often that they were not at risk of addiction 
or overdose if they were taking them as prescribed. Even 
those who felt they may be addicted sometimes viewed 
this as an acceptable trade- off for pain relief. Our find-
ings indicate that patient desperation combined with 
inadequate information from healthcare professionals 
could trigger the prescription of opioids. It may be that 
delivering accurate information about the potential side 
effects and limited efficacy of opioids for chronic pain 
management would reduce the use of opioids.
Our findings demonstrate that the stigma surrounding 
how patients feel about being on opioids can be 
compounded by the judgements of others. Although 
patients often describe themselves in terms of ‘reluc-
tant users’, if they experienced the benefits of opioids 
through decreased pain and thus increased function they 
are often too scared to reduce opioids and return to a life 
of potentially unmanaged pain.
Our findings suggest that clinicians and patients with 
chronic pain are not always ‘on the same page’. The 
theme a therapeutic alliance captures the positives, but 
also the tensions and mismatches of perceptions held by 
healthcare providers who are attempting to limit dose 
escalation, and patients who may view constant dose 
escalation as an acceptable trade- off for reducing relent-
less pain. The therapeutic alliance is a robust theme 
supported by 26 of the 31 studies included. This is not 
surprising as patients rely on their healthcare profes-
sionals to prescribe opioids. This finding resonates with 
qualitative evidence syntheses exploring the experience 
of patients13 and healthcare professionals.35 It seems 
clear that joint decision making is important for appro-
priate healthcare; however, our findings suggest that 
there are instances of mistrust on both sides. A qualita-
tive evidence synthesis exploring clinicians’ experience 
of prescribing opioids for chronic pain demonstrates 
that the process of prescribing opioids is not straight-
forward for clinicians who face a complex decision: 
"‘Should I shouldn’t I’ prescribe opioids for CNMP?"35 
They also demonstrate that clinicians must walk a fine 
line to balance the pros and cons of opioids while 
also maintaining patient trust. This suggests that both 
patients and healthcare professionals find dealing with 
prescribing/taking opioids for CNMP is complex and 
involves balancing and trade- offs.
Current guidance from the Royal College of Anaes-
thetists in the UK and the Centers for Disease Control 
and Prevention in the USA advocates a preference for 
non- opioid therapies in the treatment of CNMP.36 If 
a clinician feels that opioids are indicated, then they 
recommend a low dose for a short duration, which 
should be assessed for effectiveness and regularly evalu-
ated for benefits and harms. All but four studies in this 
review are between 2005 and 2017, prior to these guide-
lines. Opioid contracts in some areas of the USA and 
Canada can make patients feel stigmatised and judged, 
and this effect can be moderated by a good therapeutic 
relationship, and reframing these as agreements rather 
than contracts.37 Some physicians may view contracts/
agreements as necessary to guard against uncontrolled 
dose escalation, repeated demands for replacement 
of lost or misplaced medication, subversion and illicit 
opioid intake. This finding resonates with Toye et al35, 
who described the moral boundary work and social 
guardianship that clinicians associate with opioid 
prescription. Our findings suggest that this role may not 
contribute to an effective therapeutic partnership.
limitations of this study
A majority of the studies are from the USA, and the 
findings need to be taken in the context of its health 
and social care systems. Most of the articles in this qual-
itative synthesis were published or the research was 
conducted before the impact of the opioid epidemic 
became clear to regulators and the medical profession. 
Some papers discussed using opioids as a last resort, 
although the opioid epidemic, especially in the USA, 
indicates that the threshold for prescribing opioids was 
low until recent initiatives to discourage prescribing 
long- term opioids for chronic pain.38 Not all studies 
gave morphine equivalent data, so we cannot deter-
mine what proportion were taking high, medium or 
low doses. We acknowledge that our interpretation of 
the data might have been influenced by the current, 
much more critical perception of opioid use for CNMP. 
Further evidence is needed to find out if these themes 
are universal for developed countries or whether there 
are important differences.
Our conceptual framework highlights that patients 
need to constantly balance and to consider the pros and 
cons of taking opioids. This can have a profound effect 
on people’s relationships with their family, friends and 
healthcare providers and their perceived standing in the 
community, which is reflected in their careful balancing 
of disclosure. The therapeutic alliance and having a clear 
understanding of all the positive and negative aspects of 
opioids were important factors that underpinned their 
ability to maintain this fragile balance. This balance 
might also affect a person’s desire or ability to taper or 
withdraw from opioids.
The GRADE- CERQual ratings (table 2) revealed we 
had confidence in the findings, with only a few minor 
concerns and no moderate or serious concerns.
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COnCluSIOnS AnD rECOMMEnDAtIOnS fOr futurE 
rESEArCh
The first meta- ethnography on this topic revealed a 
constant balancing and a life in flux in an effort to main-
tain participation in life and relationships. These are 
important features of opioid use for CNMP. To maintain 
this delicate balance, they often need support from family 
or clinicians; however, this balance can be upset by the 
feeling of being judged by this same potential support 
system or peers and society at large through the media. 
The therapeutic alliance with healthcare professionals, 
the extent of people’s understanding, as well as the stigma 
attached to opioid use need to be navigated by people 
who are often reluctant to be on opioids in the first place.
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